DOCSLIB.ORG

Royal DSM Integrated Annual Report 2017 DSM at a Glance Nutrition DSM Nutritional Products and DSM Food Specialties Form Our Nutrition Business

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Royal DSM Integrated Annual Report 2017 DSM at a Glance Nutrition DSM Nutritional Products and DSM Food Specialties Form Our Nutrition Business Royal DSM Integrated Annual Report 2017 DSM at a glance Nutrition DSM Nutritional Products and DSM Food Specialties form our Nutrition business. DSM Nutritional Products provides solutions for animal feed, food and beverages, pharmaceuticals, infant nutrition, dietary supplements and personal care. DSM Food Specialties is a leading global supplier of specialty food enzymes, cultures, bio-preservation, hydrocolloids, savory, and sugar reduction solutions. Materials DSM’s Materials business includes DSM Engineering Plastics, DSM Dyneema, and DSM Resins & Functional Materials. DSM is a global player in specialty plastics for the electrical components and electronics, automotive, fl exible food packaging and consumer goods industries. The materials portfolio also includes Dyneema®, the world’s strongest fi ber™, as well as resins for paints, industrial applications and optical fi ber coatings. Innovation Center DSM Innovation Center accelerates the innovation power and speed of our core businesses. It also has a business development role, focusing on areas outside the current scope of the business groups. The company has three Emerging Business Areas: DSM Biomedical, DSM Bio-based Products & Services and DSM Advanced Solar. Partnerships As part of DSM’s strategic transformation and move away from more commoditized and cyclical areas, we established joint ventures: DSM Sinochem Pharmaceuticals, Patheon and ChemicaInvest. In 2017, DSM divested Patheon for proceeds of about € 1.5 billion. People Planet 21,054 75% 26% 21% Workforce Employee engagement Greenhouse-gas effi ciency Purchased electricity (at year-end 2017, index, up 4% from improvement, cumulative from renewable sources, excluding affi liates) 2016 versus 2008 (on track) up from 8% in 2016 27/73 17% 21% 3% Female/male ratio Female executives, Innovation sales as % Energy effi ciency stable versus 20161 up 2% from 2016 of total sales. Target of improvement, cumulative ~20% achieved. verus 2015. Ambition of more than 10% in 2025. 0.36 Frequency Index of 23 Recordable Injuries up Water consumption, up from from 0.33 in 20162 22 in 2016 (in million m3) 1 The companies that are not integrated into the HR systems (approx. 10% of the total workforce) are not taken into account. Brighter Living Solutions 2 Per 100 DSM employees and contractor employees. 62% Sales of Brighter Living Solutions (ECO+ / People+), aiming for 65% by 2020 Climate and energy More than 200 million solar panels contain our solutions. 90% of cars sold today contain our materials. Profi t € 8,632 € 1,445 15% Net sales (in millions) Adjusted EBITDA1 Adjusted EBITDA growth up 9% from € 7,920 (in millions) versus versus 2016 € 1,262 in 2016 +190 12.3% € 996 € 546 ROCE growth (in bps) ROCE versus 10.4% Cash provided by operating Capital expenditure versus 2016 in 2016 activities (in millions) versus (cash-based), up from € 1,018 in 2016 € 475 in 2016 (in millions) € 1,781 € 10.07 € 1.85 Net profi t (in millions), Net earnings per ordinary Proposed dividend per up from € 629 in 2016 share, versus € 3.52 ordinary share2 for 2017, in 2016 up from € 1.75 in 2016 1 See page 167 for reconciliation. 2 Subject to approval by the Annual General Meeting of Shareholders. Circular and bio-based economy From bio-based resins to fully recyclable carpets, DSM is fi nding solutions. Our materials are in virtually every mobile device on the market. Nutrition As the #1 supplier of vitamins, and with a broad portfolio of food ingredients, we support good health at every age. DSM – Bright Science. Brighter Living.™ Our purpose is to create brighter lives for people today and generations to come. We use our unique competences in health, nutrition and materials to create solutions that nourish, protect and improve performance. DSM uses Bright Science to create Brighter Living for people today and generations to come. Based on a deep understanding of key global trends that are driving societies, markets and customers, we create solutions to some of the world's biggest challenges, thus adding to both our own and our customers' success. We believe that DSM's continued success will be driven by our ability to create shared value for all stakeholders, now and in the future. Our customers derive value from being able to offer end-users improved products and services; society and the planet derive value from the impact of more sustainable, longer-lasting, safer, healthier and more nutritious alternatives; and, as a result, DSM and its shareholders derive value from stronger growth and profitability. Finally, our employees feel engaged and motivated both through the contribution they make to a better world and the success this creates for the company in which they work. More information on 'How DSM creates value for its stakeholders' can be found on page 24. DSM – Bright Science. Brighter Living.™ Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences, DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about € 10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com. © 2018 Royal DSM. All rights reserved. Bright Science. Brighter Living. 2017 www.dsm.com Table of contents 6 Key data 118 Report by the Supervisory Board 125 Remuneration policy for the Managing Board 7 Letter from the CEO 10 DSM and the Sustainable Development Goals 130 Supervisory Board and Managing Board Royal DSM 18 Report by the Managing Board 132 What still went wrong in 2017 18 Strategy 2018 24 How DSM creates value for its stakeholders 134 Information about the DSM share 26 Stakeholders 34 People 137 Sustainability statements 46 Planet 52 Profit 151 Consolidated financial statements 151 Summary of significant accounting policies 68 Review of business 158 Consolidated financial statements 68 Nutrition 164 Notes to the consolidated financial statements 82 Materials of Royal DSM 90 Innovation Center 96 Corporate Activities 215 Parent company financial statements 97 Partnerships 217 Notes to the parent company financial statements 98 Financial and reporting policies 229 Other information 98 Financial policy 229 Independent auditor's report 99 Reporting policy 234 Assurance report of the independent auditor 236 Special statutory rights 101 Corporate governance and risk management 236 Important dates 101 Introduction 104 Dutch Corporate Governance Code 237 DSM figures: five-year summary 104 Governance framework 108 DSM Code of Business Conduct 240 Explanation of some concepts and ratios 112 Risk management 117 Statements of the Managing Board 243 List of abbreviations Forward-looking statements This document may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. Examples of forward-looking statements include statements made or implied about the company's strategy, estimates of sales growth, financial results, cost savings and future developments in its existing businesses as well as the impact of future acquisitions, and the company's financial position. These statements can be management estimates based on information provided by specialized agencies or advisors. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause the company's actual performance and position to differ materially from these statements. These factors include, but are not limited to, macro-economic, market and business trends and conditions, (low-cost) competition, legal claims, the company's ability to protect intellectual property, changes in legislation, changes in exchange and interest rates, changes in tax rates, pension costs, raw material and energy prices, employee costs, the implementation of the company's strategy, the company's ability to identify and complete acquisitions and to successfully integrate acquired companies, the company's ability to realize planned divestments, savings, restructuring or benefits, the company's ability to identify, develop and successfully commercialize new products, markets or technologies, economic and/or political changes and other developments in countries and markets in which DSM operates. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the 'Risk Management' chapter. As a result, DSM's actual future performance, position and/or financial results may differ materially from the plans, goals and expectations set forth in such forward- looking statements. DSM has no obligation to update the statements contained in this document, unless required by law. The English language version of this document is leading. Bright Science. Brighter Living. 2017 5 www.dsm.com Key data Key data1 20172 20162 People Workforce at 31 December (headcount) 21,054 20,786 Female/male ratio3
Load more

Recommended publications
  • DSM's Integrated Annual Report 2015
    Royal DSM Integrated Annual Report 2015 WorldReginfo - c41a4efa-17eb-497c-8f68-03022dabfb88 WorldReginfo - c41a4efa-17eb-497c-8f68-03022dabfb88 DSM at a glance Nutrition DSM Resins & Functional Materials is a global player in developing, manufacturing and marketing high-quality resins The Nutrition cluster comprises DSM Nutritional Products and solutions for paints, industrial coatings and fiber-optic coatings. DSM Food Specialties.These businesses serve the global Continuous innovation means that customers can meet industries for animal feed, food and beverage, pharmaceutical, regulatory needs and respond better to consumer demands for infant nutrition, dietary supplements and personal care. more sustainable materials. DSM Nutritional Products is one of the world’s leading Innovation Center producers of essential nutrients such as vitamins, carotenoids, nutritional lipids and other ingredients to the feed, food, DSM Innovation Center serves as an enabler and accelerator pharmaceutical and personal care industries. Among its of innovation within DSM as well as providing support to the customers are the world’s largest food and beverage clusters. With its Emerging Business Areas, the Business companies. DSM is uniquely positioned thanks to the Incubator and DSM Venturing & Licensing, the DSM Innovation combination of its broad portfolio of active ingredients, maximum Center has a general business development role, focusing on differentiation through formulation, local presence, a global areas outside the current scope of the business groups. premix network, and a strong focus on innovation. DSM Nutritional Products consists of the following business units: DSM’s Emerging Business Areas provide strong long-term growth platforms based on the company’s core competences Animal Nutrition & Health addresses the nutritional additives in life sciences and materials sciences.
    [Show full text]
  • Royal DSM N.V. Annual Report 2006
    Royal DSM N.V. Annual Report 2006 Brighter Wider Better Together DSM Profile DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM’s products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM’s strategy, named Vision 2010 – Building on Strengths, focuses on accelerating profitable and innovative growth of the company’s specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over €8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com. Annual Report 2005 www.dsm.com DSM at a glance DSM’s activities have been grouped into business groups representing coherent product / market combinations. The business group directors report directly to the Managing Board. Nutrition Pharma €2,407m €916m DSM Nutritional Products DSM Pharmaceutical Products DSM Nutritional Products is the world’s largest supplier of nutri- DSM Pharmaceutical Products is one of the world’s leading tional ingredients, such as vitamins, carotenoids (anti-oxidants providers of high quality global custom manufacturing services and pigments), other biochemicals and fine chemicals, and to the pharmaceutical, biotech and agrochemical industries.
    [Show full text]
  • Cytoscan Assay Manual Workflow User
    CytoScan™ Assay USER GUIDE Manual Workflow Catalog Numbers 901835, 901834, 901859, 901860 Publication Number 703038 Revision 7 For Research Use Only. Not for use in diagnostic procedures. The information in this guide is subject to change without notice. DISCLAIMER TO THE EXTENT ALLOWED BY LAW, LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT. Important Licensing Information This product may be covered by one or more Limited Use Label Licenses. By use of this product, you accept the terms and conditions of all applicable Limited Use Label Licenses. Corporate entity Life Technologies | Carlsbad, CA 92008 USA | Toll Free in USA 1 800 955 6288 TRADEMARKS All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Microsoft, and Excel are either registered trademarks or trademarks of Microsoft Corporation in the United States and/or other countries. QIAGEN, Gentra and Puregene are registered trademarks of QIAGEN. Titanium is a trademark of Clontech Laboratories, Inc. Tough-Spots is a registered trademark of Diversified Biotech. ©2011, 2014, 2017 Thermo Fisher Scientific Inc. All rights reserved. Contents CHAPTER 1 Before you begin. 6 Introduction . 6 Assay warnings and precautions . 7 Genomic DNA general requirements and recommendations . 9 Sources of human genomic DNA . 10 Genomic DNA extraction/purification methods . 10 RNase treatment . 10 Controls . 10 Data analysis . 11 CHAPTER 2 CytoScan™ Assay procedure . 12 Temperature definitions . 12 Section 1: Prepare gDNA plate . 13 Dilute stock gDNA to working concentration .
    [Show full text]
  • Incoming Letter: QIAGEN N.V
    WACHTELL, LIPTON , ROSEN & KATZ MARTIN LIPTON STEVEN A. COHEN 51 W E S T 52N D S T R E E T DAVID E. SHAPIRO SABASTIAN V. NILES HERBERT M. WACHTELL DEBORAH L. PAUL DAMIAN G. DIDDEN ALISON ZIESKE PREISS THEODORE N. MIRVIS DAVID C. KARP NEW YORK, N.Y. 1 0 0 1 9 - 6 1 5 0 IAN B OC Z K O TIJANA J. DVORNIC EDWARD D. HERLIHY RICHARD K. KIM MATTHEW M. GUEST JENNA E. LEVINE DANIEL A. NEFF JOSHUA R. CAMMAKER TELEPHONE: (212) 403 -1000 DAVID E. KAHAN RYAN A. McLEOD ANDREW R. BROWNSTEIN MARK GORDON DAVID K. LAM ANITHA REDDY MARC WOLINSKY JOSEPH D. LARSON FACSIMILE: (212) 403 -2000 BENJAMIN M. ROTH JOHN L. ROBINSON STEVEN A. ROSENBLUM JEANNEMARIE O’BRIEN JOSHUA A. FELTMAN JOHN R. SOBOLEWSKI JOHN F. SAVARESE WAYNE M. CARLIN GEORGE A. KATZ (1965 -1 9 8 9) ELAINE P. GOLIN STEVEN WINTER SCOTT K. CHARLES STEPHEN R. D iPRIMA JAMES H. FOGELSON (1967 - 1 9 91) EMI L A. KLEINHAUS EMILY D. JOHNSON JODI J. SCHWARTZ NICHOLAS G. DEMMO LEONARD M. ROSEN (1965 - 2 0 14 ) KARESSA L. CAIN JACOB A. KLING ADAM O. EMMERICH IGOR KIRMAN RONALD C. CHEN RAAJ S. NARAYAN RALPH M. LEVENE JONATHAN M. MOSES OF C O UN S EL GORDON S. MOODIE VIKTOR SAPEZHNIKOV RICHARD G. MASON T. EIKO STANGE DONGJU SONG MICHAEL J. SCHOBEL MARTIN J.E. ARMS ERIC S. ROBINSON DAVID M. SILK JOHN F. LYNCH BRADLEY R. WILSON ELINA TETELBAUM MICHAEL H. BYOWITZ PATRICIA A. ROBINSON* ROBIN PANOVKA WILLIAM SAVITT GRAHAM W.
    [Show full text]
  • DCAT MEMBER COMPANY MEETING LOCATOR V. 4
    DCAT MEMBER COMPANY MEETING LOCATOR v. 4 THE BENJAMIN Sancilio Pharmaceuticals Company, Inc. Sri Krishna Pharmaceuticals Ltd. Amino Chemicals Ltd. Zydus Pharmaceuticals (USA) Inc. Apogee Pharma, Inc. C2 PHARMA INTERCONTINENTAL BARCLAY Calyx Chemicals & Pharmaceuticals Ltd. AbbVie* ChemCon GmbH ACIC Pharmaceuticals Inc. Concord Biotech Limited Advitech SA Dipharma Francis Srl Amneal Pharmaceuticals LLC DSM Sinochem Pharmaceuticals ALP Pharm F.I.S. - Fabbrica Italiana Sintetici S.p.A. AMRI Jost Chemical Co. Asymchem Inc. Jubilant Pharma Capsugel, Now a Lonza Company* PharmSource, A GlobalData Company CBC AMERICAS Corp. PolyPeptide Group CellMark USA, LLC ROHNER Inc. Charioteer Pharmaceutical Co., Ltd., Zhejiang FIFTY NYC, A AFFINA HOTEL Chemical and Pharmaceutical Solutions Chiral Quest Corp. Chartwell Pharmaceuticals, LLC Croda, Inc. HOTEL 48LEX DFE Pharma AB BioTechnologies, Inc. DPL-US AiPing Pharmaceutical, Inc. EQ Esteve Almac Evonik Corporation Aptuit LLC FAREVA SA AZAD Fine Chemicals Ltd. Flavine North America, Inc. Cambridge Isotope Laboratories, Inc. Formosa Laboratories, Inc. CMC Biologics Grifols International S.A. Groupe Parima Hainan Poly Pharm. Co., Ltd. Navin Fluorine International Limited Harris Pharmaceutical Qualicaps, Inc. Helm AG RC2 Pharma Connect LLC Hetero USA, Inc. Recipharm Hikal, Ltd. Recro Gainesville LLC Interchem Corporation Reed-Lane, Inc. Inventia Healthcare PVT LTD Please note: Some DCAT member companies have requested not to be listed in the locator. (*) indicates member companies with Business Meeting Spaces in more than one hotel. INTERCONTINENTAL BARCLAY CONT'D PiSA BioPharm, Inc. SPI Pharma Inc. Johnson Matthey Tapemark Kingchem Life Science LLC Unither Pharmaceutical Legacy Pharmaceutical Packaging Uquifa S.A. Lonza AG* Neuland Laboratories Ltd. LOTTE NY PALACE Orion Group AbbVie* Par Pharmaceutical, Inc.
    [Show full text]
  • Life Sciences in Utah Read
    EDCUTAH INDUSTRY PROFILE | FY 18-19 LIFE SCIENCES IN UTAH MAJOR UNIVERSITIES AND COLLEGES MAJOR EMPLOYERS ON THE COVER 1 Utah State University 4 Westminster College 6 Utah Valley University 9 Dixie State University 1 Paragon Medical Edwards Lifesciences Sapien 3 Heart Valve 2 Weber State University 5 Salt Lake 7 Brigham Young University 10 Rocky Vista University Community College 2 USU Research The Edwards Sapien 3 Transcatheter Heart Valve is changing 3 University of Utah 8 Southern Utah University Foundation the world of aortic stenosis therapy. In 2016 the Sapien 3 3 Fresenius USA received FDA approval for expanded use in the treatment of Manufacturing 4 Allergan intermediate-risk patients. The valve has the highest survival (formerly Actavis) rate ever reported in a TAVI clinical trial. 5 ARUP Laboratories LOGAN 6 Bard Access Systems 1 1 1 2 7 BioFire Diagnostics 8 Blackrock Microsystem 9 Biomerics 10 Clinical OGDEN Innovations 2 2 3 11 GE Healthcare 4 12 Great Basin 3 4 A 3 Scientific 4 SALT LAKE CITY 13 ICU Medical 5 A 6 14 Lineagen B 15 Myriad Genetic 4 Laboratories C 16 Nelson Laboratories 5 34 17 Otto Bock PROVO Healthcare 6 7 18 Pra Health Personalized Medicine, Medical Devices, Sciences 19 Recursion Pharmaceuticals 20 Sorenson World Class Research Genomics 21 Stryker Industry • In 2015, Utah’s post-performance tax incentives 22 Teva Pharma • Utah is proud to be home to companies like Merit facilitated nearly 25,000 new jobs and more than ceuticals Industries, (formerly Anesta, Medical Systems, BD (Becton Dickinson), Edwards $65M in new state revenue.
    [Show full text]
  • Thermo Fisher Scientific Inc. 168 Third Avenue Waltham, Massachusetts 02451, U.S.A
    Thermo Fisher Scientific Inc. 168 Third Avenue Waltham, Massachusetts 02451, U.S.A. THERMO FISHER SCIENTIFIC INC. 2007 EMPLOYEES' STOCK PURCHASE PLAN AS AMENDED AND RESTATED (THE "ESPP") Prospectus for the employees of certain European Economic Area ("EEA") subsidiaries of Thermo Fisher Scientific Inc., subject to the applicable legislation in each country Pursuant to articles L. 412-1 and L. 621-8 of the Code monétaire et financier and its General Regulation, in particular articles 211-1 to 216-1 thereof, the Autorité des marchés financiers ("AMF") has attached visa number 18-540 dated November 28, 2018, onto this prospectus. This prospectus was established by the issuer and incurs the responsibility of its signatories. The visa, pursuant to the provisions of Article L. 621-8-1-I of the Code monétaire et financier, was granted after the AMF verified that the document is complete and comprehensible, and that the information it contains is consistent. The visa represents neither the approval of the worthiness of the operation nor the authentication of the financial and accounting information presented. This prospectus will be made available in printed form to employees of the EEA subsidiaries of Thermo Fisher Scientific Inc. based in countries in which an offering under the ESPP is considered a public offering, subject to the applicable legislation in each country, at the respective head offices of their employers. In addition, this prospectus along with summary translations (as applicable) will be posted on Thermo Fisher Scientific Inc.’s intranet and free copies will be available to the employees upon request by contacting the human resources departments of their employers.
    [Show full text]
  • Corporate Social Responsibility
    2016 REPORT Corporate Social Responsibility Discover more at thermofisher.com/csr Thermo Fisher Scientific is the world leader in serving science, We have one Mission: generating $18 billion in annual revenue. Customers worldwide trust to enable our customers the products and solutions available through our premier brands to help them accelerate innovation and enhance productivity. to make the world healthier, cleaner and safer. Together, we are making a difference in the world. Letter from our CEO I am incredibly proud of the work we do at Thermo Fisher Scientific to fulfill our Mission: to enable our customers to make the world healthier, cleaner and safer. We have an extraordinary team of colleagues around the world who are committed to partnering with our customers to help them be successful. Whether they are developing cures for cancer, protecting the environment or making sure our food is safe, our customers look to us for solutions to some of the greatest challenges of this century. The way we approach our work is grounded by our 4i Values of Integrity, Intensity, Innovation and Involvement. These values guide our interactions with our customers and within the company, creating a culture where diverse perspectives are not only accepted, Marc N. Casper but also encouraged. Our colleagues are empowered to make a difference so they can President and CEO fulfill our Mission and their own career aspirations – which is the foundation of our success. Business sustainability We continually pursue new technology innovations and streamline our processes to ensure we are This corporate social responsibility (CSR) report highlights our key initiatives within the three pillars of our CSR strategy: business sustainability, employee involvement and philanthropic giving.
    [Show full text]
  • Our Mission in Action
    434105 QX9_Thermo Fisher 8.25 x 11 Grid 7/3/13 9:32 PM Page COV1 Our mission in action 2012 CORPORATE SOCIAL RESPONSIBILITY REPORT 434105 QX9_Thermo Fisher 8.25 x 11 Grid 7/1/13 11:20 AM Page COV2 We enable our customers to make the world healthier, cleaner and safer. CONTENTS Page 1 CEO Message Page 2 CSR Approach Page 3 About Thermo Fisher Scientific Page 6 Dedicated to Discovery Our Business Page 10 Making Connections, Creating Value Our Employees Page 13 Inspiring Education Our Philanthropy Page 18 Our Report Page 19 Global Reporting Initiative Index 434105 QX9_Thermo Fisher 8.25 x 11 Grid 7/1/13 11:20 AM Page 1 From Our CEO Thermo Fisher Scientific is the world leader in serving science. Our mission — to enable our customers to make the world healthier, cleaner and safer — perfectly captures our commitment to corporate social responsibility and sustainable growth. Globally, we provide state-of-the-art products and services that help our customers meet their own goals for sustainable growth, from specialty diagnostic tests to improve patient care, to air-quality systems that monitor stack emissions, to meters that ensure the safety of our drinking water. During 2012, we launched a number of innovative new products that improve healthcare and the environment, including: • Breakthrough advances in spectroscopy that help research scientists improve efficiency during experiments and accelerate results, • Continuous particulate monitors that measure microscopic airborne particles to assess the quality of the air we breathe, and • Bioprocessing media and systems to help biotech companies develop vaccines that dramatically reduce illness, especially among children.
    [Show full text]
  • Genomic Surveillance: Inside China's DNA Dragnet
    Genomic surveillance Inside China’s DNA dragnet Emile Dirks and James Leibold Policy Brief Report No. 34/2020 About the authors Emile Dirks is a PhD candidate in political science at the University of Toronto. Dr James Leibold is an Associate Professor and Head of the Department of Politics, Media and Philosophy at La Trobe University and a non-resident Senior Fellow at ASPI. Acknowledgements The authors would like to thank Danielle Cave, Derek Congram, Victor Falkenheim, Fergus Hanson, William Goodwin, Bob McArthur, Yves Moreau, Kelsey Munro, Michael Shoebridge, Maya Wang and Sui-Lee Wee for valuable comments and suggestions with previous drafts of this report, and the ASPI team (including Tilla Hoja, Nathan Ruser and Lin Li) for research and production assistance with the report. ASPI is grateful to the Institute of War and Peace Reporting and the US State Department for supporting this research project. What is ASPI? The Australian Strategic Policy Institute was formed in 2001 as an independent, non-partisan think tank. Its core aim is to provide the Australian Government with fresh ideas on Australia’s defence, security and strategic policy choices. ASPI is responsible for informing the public on a range of strategic issues, generating new thinking for government and harnessing strategic thinking internationally. ASPI International Cyber Policy Centre ASPI’s International Cyber Policy Centre (ICPC) is a leading voice in global debates on cyber and emerging technologies and their impact on broader strategic policy. The ICPC informs public debate and supports sound public policy by producing original empirical research, bringing together researchers with diverse expertise, often working together in teams.
    [Show full text]
  • Integrated Reporting As a Driver for Integrated Thinking?
    Integrated Reporting as a driver for Integrated Thinking? Maturity of <IR> in the Netherlands 2015 Contributors Patrick Seinstra Jennifer Muller Royal BAM Group: Barry Oesman Partner Integrated & Sustainability Deloitte Audit Master Student at London School of Economics and Group Controller Political Science Anneke Sipkens DSM: Kimberley Chan Director Sustainability Deloitte Risk Services Michiel van der Valk Sustainability Manager Master Student Sustainable Business & Innovation at Udeke Huiskamp Utrecht University Nutreco: Jose Villalon Senior Manager Sustainability Deloitte Risk Services Corporate Sustainability Director CSR the Netherlands (MVO Nederland) Erica Kostense-Smit Willem Lageweg Nutreco: Sigrid van Amerongen Manager Sustainability Deloitte Risk Services CEO CSR The Netherlands (MVO Nederland) CSR Manager Ashley Myers Vincent van Marle Heineken International: Jan-Willem Vosmeer Manager Sustainability Deloitte Risk Services Manager CSR Manager Frank Geelen Interviewees Delta Lloyd: David Hoppe Partner CFO Services & Finance Transformation NS: Carola Wijdoogen Communications Advisor Deloitte Consulting Director Sustainable Business Ministry of Economic Affairs: Martin Lok Marco van der Vegte KPN: Hans Koeleman Program Manager Natural Capital Managing Partner Audit and Member Executive Board Director Corporate Communications & CSR Deloitte Holding Avans Hogeschool: Marleen Janssen Groesbeek KPN: Brechtje Spoorenberg Professor Sustainable Finance and Accounting Olivier van Thuijl Manager CSR Senior Manager CFO Services Deloitte
    [Show full text]
  • THERMO FISHER SCIENTIFIC INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2018 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 04-2209186 (State of incorporation or organization) (I.R.S. Employer Identification No.) 168 Third Avenue Waltham, Massachusetts 02451 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (781) 622-1000 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which Name of each exchange on which Title of each class registered Title of each class registered Common Stock, $1.00 par value New York Stock Exchange 2.000% Notes due 2025 New York Stock Exchange Floating Rate Notes due 2019 New York Stock Exchange 1.400% Notes due 2026 New York Stock Exchange Floating Rate Notes due 2020 New York Stock Exchange 1.450% Notes due 2027 New York Stock Exchange 1.500% Notes due 2020 New York Stock Exchange 1.375% Notes due 2028 New York Stock Exchange 2.150% Notes due 2022 New York Stock Exchange 1.950% Notes due 2029 New York Stock Exchange 0.750% Notes due 2024 New York Stock Exchange 2.875% Notes due 2037 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]